Hospital Pequeno Principe | Nucleo de Pesquisa

Research site

(Unclaimed)

Location

Rua Desembargador Motta, 1070, Curitiba, Parana, Brazil

Site insights

Top conditions

Top treatments

Finerenone

AZ-3102

Nizubaglustat

Anidulafungin

Carfilzomib

Selexipag

Golimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 13 total trials

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (SALTO)

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with...

Active, not recruiting

Hypertension, Pulmonary

Drug: Selexipag

Drug: Placebo

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PURSUIT 2)

The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participant...

Active, not recruiting

Colitis, Ulcerative

Drug: Infliximab

Drug: Golimumab

Locations recently updated

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-31...

Enrolling

Gangliosidosis, GM1

Gangliosidoses, GM2

Drug: AZ-3102

Drug: Placebo

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-31...

Enrolling

Niemann-Pick Type C Disease

Drug: Nizubaglustat

Drug: Placebo

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction (FIORELLO)

Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD)....

Begins enrollment in 2 months

Heart Failure (Pediatric)

Left Ventricular Systolic Dysfunction

Drug: Finerenone (Kerendia, BAY94-8862)

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling

Chronic Kidney Disease

Proteinuria

Drug: Finerenone (Kerendia, BAY94-8862)

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction (FIORE)

Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is...

Not yet enrolling

Left Ventricular Systolic Dysfunction

Heart Failure (Pediatric)

Drug: Placebo

Drug: Finerenone (Kerendia, BAY94-8862)

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling

Chronic Kidney Disease

Proteinuria

Drug: Finerenone (Kerendia, BAY94-8862)

Drug: Placebo

Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease (RAINBOW)

This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safet...

Active, not recruiting

Niemann-Pick Disease, Type C

GM2 Gangliosidosis

Drug: AZ-3102 (Dose 1)

Drug: AZ-3102 (Dose 2)